<unk>  is absolutely contraindicated in patients who have taken therapeutic doses of opioids for more than seven consecutive days immediately prior to when<unk>  would be initiated because individuals with recent exposure to opioids are expected to be more sensitive to the effects of μ-opioid receptor antagonists. The peripheral site of action of<unk>  suggests that such a heightened sensitivity would precipitate gastrointestinal effects beyond dyspepsia.
Alvimopan
Fenoldopam
Tofisopam
Avacopan
Levosimendan
Hexoprenaline
Ergotamine
Bethanechol